Pharmafile Logo

Frontera London

- PMLiVE

AstraZeneca’s oncology renaissance

Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...

New editor adds microscopic attention to detail at Porterhouse Medical

The Porterhouse Medical Group is delighted to welcome Isabel Thomas to our scientific services team in Reading.Joining us as an associate editor, Isabel will be working closely alongside Stephanie, senior editor, to boost...

Porterhouse Medical Group

- PMLiVE

Brexit contributes to surge in generic drug prices

Calls for government to protect pharmacies

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

Navigating the antibiotic resistance crisis

Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Blue Latitude Health

- PMLiVE

‘No deal’ Brexit could see pharmacists take lead amid drug shortages

Government steps up preparations as Brexit day nears

- PMLiVE

Combined immunotherapies – potential and pitfalls

‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’

- PMLiVE

Lilly partners with AC Immune on tau drug for Alzheimer’s

Potential payments of $1.7bn to Swiss firm

- PMLiVE

Blue Latitude Health joins Fishawack Group of Companies

Blue Latitude Health announces a new partnership with Fishawack Group of Companies, fuelling our global growth.

Blue Latitude Health

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links